All patients
Age < 65y (younger) Age > 65y cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mNSCLC - L2 - all population, anti-PD-(L)1 vs. taxanes, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 078, 2019 0.68 [0.52; 0.89]
JAVELIN Lung 200 (all population), 2018 0.90 [0.75; 1.08]
OAK (all population), 2016 0.80 [0.70; 0.92]
POPLAR, 2016 0.73 [0.53; 1.00]
0.80 [0.72 ; 0.89 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, OAK (all population), 2016, POPLAR, 2016 4 8% 2,808 moderate not evaluable deaths (OS) (extension)detailed results CheckMate 078, 2019 0.75 [0.61; 0.93]
0.75 [0.61 ; 0.93 ] CheckMate 078, 2019 1 0% 504 NA not evaluable PFS (extension)detailed results CheckMate 078, 2019 0.79 [0.64; 0.97]
0.79 [0.64 ; 0.97 ] CheckMate 078, 2019 1 0% 504 NA not evaluable progression or deaths (PFS)detailed results CheckMate 078, 2019 0.77 [0.62; 0.95]
JAVELIN Lung 200 (all population), 2018 1.16 [0.97; 1.39]
OAK (all population), 2016 0.96 [0.85; 1.08]
POPLAR, 2016 0.94 [0.72; 1.23]
0.95 [0.82 ; 1.11 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, OAK (all population), 2016, POPLAR, 2016 4 63% 2,808 moderate not evaluable objective responses (ORR)detailed results CheckMate 078, 2019 4.40 [1.99; 9.74]
JAVELIN Lung 200 (all population), 2018 1.40 [0.92; 2.13]
OAK (all population), 2016 1.19 [0.85; 1.67]
POPLAR, 2016 0.99 [0.52; 1.91]
1.52 [0.95 ; 2.42 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, OAK (all population), 2016, POPLAR, 2016 4 70% 2,808 moderate not evaluable objective responses (ORR) (extension)detailed results CheckMate 078, 2019 4.80 [2.14; 10.77]
4.80 [2.14 ; 10.77 ] CheckMate 078, 2019 1 0% 504 NA not evaluable AE (any grade)detailed results OAK (all population), 2016 0.66 [0.39; 1.13]
POPLAR, 2016 0.87 [0.26; 2.93]
0.69 [0.42 ; 1.13 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable AE (grade 3-4)detailed results OAK (all population), 2016 0.51 [0.41; 0.65]
POPLAR, 2016 0.60 [0.38; 0.97]
0.53 [0.43 ; 0.65 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable AE leading to death (grade 5)detailed results OAK (all population), 2016 0.67 [0.30; 1.53]
POPLAR, 2016 1.15 [0.34; 3.85]
0.80 [0.40 ; 1.57 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results OAK (all population), 2016 0.58 [0.45; 0.75]
POPLAR, 2016 0.29 [0.14; 0.61]
0.45 [0.24 ; 0.87 ] OAK (all population), 2016, POPLAR, 2016 2 66% 1,464 moderate not evaluable SAE (any grade)detailed results POPLAR, 2016 1.05 [0.64; 1.73]
1.05 [0.64 ; 1.73 ] POPLAR, 2016 1 0% 277 NA not evaluable SAE (grade 3-4)detailed results OAK (all population), 2016 1.03 [0.80; 1.31]
1.03 [0.80 ; 1.31 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable STRAE (any grade)detailed results CheckMate 078, 2019 0.59 [0.34; 1.02]
JAVELIN Lung 200 (all population), 2018 0.37 [0.24; 0.57]
0.45 [0.28 ; 0.71 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 42% 1,251 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 078, 2019 0.34 [0.18; 0.66]
0.34 [0.18 ; 0.66 ] CheckMate 078, 2019 1 0% 493 NA not evaluable TRAE (any grade)detailed results CheckMate 078, 2019 0.35 [0.22; 0.57]
JAVELIN Lung 200 (all population), 2018 0.29 [0.21; 0.42]
OAK (all population), 2016 0.29 [0.22; 0.39]
POPLAR, 2016 0.27 [0.15; 0.51]
0.30 [0.25 ; 0.36 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, OAK (all population), 2016, POPLAR, 2016 4 0% 2,715 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.15 [0.10; 0.24]
JAVELIN Lung 200 (all population), 2018 0.12 [0.08; 0.18]
OAK (all population), 2016 0.23 [0.18; 0.31]
POPLAR, 2016 0.20 [0.11; 0.38]
0.17 [0.12 ; 0.24 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, OAK (all population), 2016, POPLAR, 2016 4 61% 2,715 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 078, 2019 0.61 [0.14; 2.77]
JAVELIN Lung 200 (all population), 2018 0.19 [0.05; 0.68]
OAK (all population), 2016 0.47 [0.02; 14.16]
POPLAR, 2016 0.31 [0.03; 3.04]
0.32 [0.13 ; 0.75 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, OAK (all population), 2016, POPLAR, 2016 4 0% 2,715 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 078, 2019 0.66 [0.32; 1.37]
JAVELIN Lung 200 (all population), 2018 0.47 [0.29; 0.77]
POPLAR, 2016 0.07 [0.02; 0.29]
0.35 [0.14 ; 0.87 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, POPLAR, 2016 3 74% 1,528 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 078, 2019 0.80 [0.33; 1.95]
0.80 [0.33 ; 1.95 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
0.66 [0.04 ; 10.50 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 1.86 [0.06; 55.60]
1.86 [0.06 ; 55.60 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
0.66 [0.04 ; 10.50 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.15 [0.02; 1.47]
JAVELIN Lung 200 (all population), 2018 0.03 [0.00; 0.44]
0.08 [0.01 ; 0.44 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.46 [0.02 ; 13.86 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Asthenia TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.06 [0.01; 0.49]
0.06 [0.01 ; 0.49 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 3.73 [0.17; 82.97]
1.67 [0.15 ; 19.05 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 0.07 [0.00; 1.15]
0.13 [0.01 ; 1.31 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.93 [0.03; 27.74]
JAVELIN Lung 200 (all population), 2018 0.11 [0.01; 2.18]
0.28 [0.03 ; 2.60 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Dyspnoea TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.04; 5.13]
0.46 [0.04 ; 5.13 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.27 [0.06; 1.15]
JAVELIN Lung 200 (all population), 2018 0.09 [0.01; 0.71]
0.19 [0.06 ; 0.62 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.01 [0.00; 0.20]
0.01 [0.00 ; 0.20 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.93 [0.03; 27.74]
0.93 [0.03 ; 27.74 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Headache TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.46 [0.02 ; 13.86 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 1.39 [0.14; 13.49]
1.39 [0.14 ; 13.49 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.23 [0.01; 6.90]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.33 [0.03 ; 3.62 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Hypertension TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 1.86 [0.17; 20.62]
1.86 [0.17 ; 20.62 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 1.86 [0.06; 55.60]
1.02 [0.08 ; 13.37 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.03; 7.42]
0.46 [0.03 ; 7.42 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.03; 7.42]
JAVELIN Lung 200 (all population), 2018 3.73 [0.17; 82.97]
1.17 [0.15 ; 9.26 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 3.74 [0.42; 33.65]
3.74 [0.42 ; 33.65 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 5.64 [0.68; 47.10]
2.85 [0.32 ; 25.34 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 17% 1,251 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.02 [0.00; 0.18]
JAVELIN Lung 200 (all population), 2018 0.05 [0.00; 0.78]
0.03 [0.01 ; 0.16 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.11 [0.01; 2.18]
0.11 [0.01 ; 2.18 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Myalgia TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.15 [0.01 ; 3.08 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
0.93 [0.02 ; 46.93 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Nausea TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.15 [0.01 ; 3.08 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.03 [0.01; 0.15]
JAVELIN Lung 200 (all population), 2018 0.01 [0.00; 0.13]
0.03 [0.01 ; 0.09 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.46 [0.02 ; 13.86 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.15 [0.01 ; 3.08 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.15 [0.01 ; 3.08 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.46 [0.02 ; 13.86 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.09 [0.00; 1.68]
0.09 [0.00 ; 1.68 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 078, 2019 3.74 [0.20; 71.10]
JAVELIN Lung 200 (all population), 2018 2.80 [0.29; 27.04]
3.12 [0.52 ; 18.80 ] CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 2 0% 1,251 moderate not evaluable Pruritus generalised TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
0.93 [0.02 ; 46.93 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 078, 2019 2.79 [0.14; 56.11]
2.79 [0.14 ; 56.11 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 6.60 [0.37; 116.99]
6.60 [0.37 ; 116.99 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Sepsis TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.23 [0.01; 5.14]
0.23 [0.01 ; 5.14 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 2.79 [0.14; 56.11]
2.79 [0.14 ; 56.11 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.15 [0.01 ; 3.08 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Vomiting TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.15 [0.01 ; 3.08 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.93 [0.06; 14.90]
0.93 [0.06 ; 14.90 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Alopecia AE (grade 3-4)detailed results OAK (all population), 2016 0.47 [0.02; 14.16]
0.47 [0.02 ; 14.16 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Anaemia AE (grade 3-4)detailed results OAK (all population), 2016 0.39 [0.21; 0.73]
0.39 [0.21 ; 0.73 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Arthralgia AE (grade 3-4)detailed results OAK (all population), 2016 2.86 [0.30; 27.54]
2.86 [0.30 ; 27.54 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Asthenia AE (grade 3-4)detailed results OAK (all population), 2016 0.58 [0.24; 1.41]
0.58 [0.24 ; 1.41 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Back pain AE (grade 3-4)detailed results OAK (all population), 2016 1.67 [0.49; 5.73]
1.67 [0.49 ; 5.73 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Constipation AE (grade 3-4)detailed results OAK (all population), 2016 1.90 [0.17; 21.02]
1.90 [0.17 ; 21.02 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Cough AE (grade 3-4)detailed results OAK (all population), 2016 1.90 [0.17; 21.02]
1.90 [0.17 ; 21.02 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Decreased appetite AE (grade 3-4)detailed results OAK (all population), 2016 0.21 [0.04; 0.97]
0.21 [0.04 ; 0.97 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Diarrhoea AE (grade 3-4)detailed results OAK (all population), 2016 0.34 [0.11; 1.08]
0.34 [0.11 ; 1.08 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Dysgeusia AE (grade 3-4)detailed results OAK (all population), 2016 0.95 [0.02; 47.91]
0.95 [0.02 ; 47.91 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Dyspnoea AE (grade 3-4)detailed results OAK (all population), 2016 1.02 [0.49; 2.13]
1.02 [0.49 ; 2.13 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Fatigue AE (grade 3-4)detailed results OAK (all population), 2016 0.69 [0.37; 1.31]
0.69 [0.37 ; 1.31 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results OAK (all population), 2016 0.01 [0.00; 0.10]
0.01 [0.00 ; 0.10 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Myalgia AE (grade 3-4)detailed results OAK (all population), 2016 0.24 [0.03; 2.12]
0.24 [0.03 ; 2.12 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Nausea AE (grade 3-4)detailed results OAK (all population), 2016 1.90 [0.35; 10.44]
1.90 [0.35 ; 10.44 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Neutropenia AE (grade 3-4)detailed results OAK (all population), 2016 0.03 [0.01; 0.11]
0.03 [0.01 ; 0.11 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results OAK (all population), 2016 0.07 [0.00; 1.18]
0.07 [0.00 ; 1.18 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results OAK (all population), 2016 0.32 [0.03; 3.04]
0.32 [0.03 ; 3.04 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Pyrexia AE (grade 3-4)detailed results OAK (all population), 2016 0.95 [0.06; 15.21]
0.95 [0.06 ; 15.21 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Stomatitis AE (grade 3-4)detailed results OAK (all population), 2016 0.08 [0.01; 0.66]
0.08 [0.01 ; 0.66 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Vomiting AE (grade 3-4)detailed results OAK (all population), 2016 0.47 [0.09; 2.59]
0.47 [0.09 ; 2.59 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 01:36 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 37
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563